~~UNITED~~OMB ~~STATES~~APPROVAL ~~SECURITIES~~OMB ~~AND~~Number: ~~EXCHANGE~~3235-0060 ~~COMMISSION~~Expires: February 28, 2013 Estimated average burden hours per response........5.00

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

~~Pursuant~~Date toof ~~Section~~Report 13(Date orof ~~15(d~~earliest event reported): of

~~the~~________July ~~Securities~~27, ~~and Exchange Act of 1934~~2014___________________

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Nearest event reported): July 22, 2014

BIOCUBE, INC.

(Exact ~~Name~~name of ~~Registrant~~registrant as ~~Specified~~specified in its ~~Charter~~charter)

Delaware	333-137920	20-3547389
(State of Organization)	(Commission File Number)	(I.R.S. Employer
		Identification No.)

DELAWARE

10State ~~BLACKLEDGE~~or ~~COURT,~~Other ~~CLOSTER~~Jurisdiction NJof ~~07624~~Incorporation

~~________________________________________________~~333-137920

~~(Address of principal executive offices)~~20-3547389

~~Registrant’s~~(Commission ~~telephone~~File ~~number, including area code: (201~~Number)~~750-2001~~

~~Check~~(IRS ~~the~~Employer ~~appropriate~~Identification ~~box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:~~Number)

¨10 ~~Written~~Blackledge ~~communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)~~Court

¨Closter, ~~Soliciting~~NJ ~~material pursuant to Rule 14a-12 under the Merger Act (17 CFR 240.14a -12)~~07624

~~¨ Pre-commencement communications pursuant to Rule 14d-2~~(b)Address ~~under~~of ~~the~~principal ~~Merger~~executive ~~Act~~offices, ~~(17~~zip ~~CFR 240.14d -2(b~~code))

~~¨ Pre-commencement communications pursuant to Rule 13e-4~~(c201) ~~under the Merger Act (17 CFR 240.13e~~ 750-~~4(c))~~2001

~~ITEM~~Registrant’s ~~4.01.~~telephone ~~CHANGES~~number, INincluding ~~REGISTRANT’S~~area ~~CERTIFYING ACCOUNTANT.~~code

~~(a)~~_________________________________________________________________________________ ~~Dismissal of Independent Registered Public Accounting Firm~~

~~On July 22, 2014, Moss, Krusick & Associates, LLC~~ (~~“Moss”)~~Former ~~was~~name ~~dismissed~~or asformer ~~the independent registered public accounting firm of BioCube~~address, ~~Inc.~~if ~~(the~~changed ~~“Company”). The~~since ~~Company’s~~last ~~Board of Directors, acting in the capacity of an audit committee, approved the dismissal of Moss~~report.)

~~Moss’s~~Check ~~reports on~~ the ~~Company’s~~appropriate ~~financial~~box ~~statements~~below ~~for~~if the ~~years~~Form ~~ended~~8-K ~~January~~filing ~~31,~~is ~~2013~~intended ~~and~~to ~~2012,~~simultaneously ~~respectively,~~satisfy ~~did~~the ~~not~~filing ~~contain~~obligation ~~any adverse opinion or disclaimer~~ of ~~opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles except that~~ the ~~reports~~registrant ~~for~~under ~~both~~any ~~years~~of ~~indicated that~~ the ~~Company~~following isprovisions in(see ~~the~~General ~~development~~Instruction ~~stage and has suffered operating losses~~A. ~~Accordingly,~~2. ~~such~~below): reports indicated that there was substantial doubt as to the Company’s ability to continue as a going concern and that the financial statements did not include any adjustments that might result from the outcome of this uncertainty.

~~During~~[ ~~the~~] ~~years~~Written ~~ended~~communications ~~January~~pursuant 31, 2013 and 2012, and through July 22, 2014, there were no disagreements with Moss on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to ~~the~~Rule ~~satisfaction~~425 ofunder ~~Moss, would have caused it to make reference thereto in connection with its reports on~~ the ~~financial~~Securities ~~statements~~Act ~~for~~(17 ~~such~~CFR ~~years~~230. ~~During the years ended January 31, 2013 and 2012, and through July 22, 2014, there were no matters that were either the subject of a disagreement as defined in Item 304(a~~425)~~(1)(iv)~~ ~~of Regulation S-K or a reportable event as described in Item 304(a)(1)(v) of Regulation S-K.~~

~~The~~[ ~~Company~~] ~~provided~~Soliciting ~~Moss~~material ~~with~~pursuant ~~a copy of the foregoing disclosures and requested Moss~~ to ~~furnish~~Rule ~~the~~14a-12 ~~Company~~under ~~with a letter addressed to~~ the ~~Securities and~~ Exchange ~~Commission~~Act ~~stating~~(17 ~~whether~~CFR ~~or not Moss agrees with the disclosures~~240. ~~A copy of Moss’s letter is filed as Exhibit 16.1 to this Current Report on Form 8~~14a-K.12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) ~~New~~under ~~Independent~~the ~~Registered~~Exchange ~~Public~~Act ~~Accounting~~(17 ~~Firm~~CFR 240.14d-2(b))

On[ ~~July~~] ~~23,~~Pre ~~2014,~~commencement ~~the~~communications ~~Company’s~~pursuant ~~Board~~to ofRule ~~Directors,~~13e ~~acting in the capacity of an audit committee, engaged Li and Company, PC~~ 4(~~“Li”~~c) asunder the ~~Company’s~~Exchange ~~new~~Act ~~independent~~(17 ~~registered~~CFR ~~public accounting firm to act as the principal accountant to audit the Company’s financial statements~~240. ~~During~~13e the Company’s fiscal years ended January 31, 2013 and 2012, and through July 23, 2014, neither the Company, nor anyone acting on its behalf, consulted with Li regarding the application of accounting principles to a specific completed or proposed transaction or the type of audit opinion that might be rendered on the Company’s financial statements, and no written report or oral advice was provided that Li concluded was an important factor considered by the Company in reaching a decision as to any such accounting, auditing or financial reporting issue.4(c))

~~Item~~Section ~~9.01.~~1 ~~Financial Statements and Exhibits.~~

Exhibit No.		Description
16.1		Letter to the Securities and Exchange Commission from Moss, Krusick & Associates, LLC regarding the matters disclosed in Item 4.01 of this Current Report on Form 8-K.

Registrant’s Business and Operations

2ITEM 1.01 Entry into a Material Definitive Agreement

~~SIGNATURES~~On July 27, 2014, BioCube, Inc. (the “Company”) entered into an Asset Purchase Agreement with Innovative Holdings, Inc., a New Jersey corporation (“Innovative”), whereby the Company agreed to purchase from Innovative certain assets in exchange for 2,000,000 restricted common shares of the Company and a convertible promissory note in the amount of $25,000 (the “Agreement”). The specific assets related to mobile applications for patients of medical marijuana facilities in Canada and the United States, as follows:

~~Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~·

Date: July 25, 2014	BIOCUBE, INC.
	By:	/s/ Boris Rubizhevsky
		Name: Boris Rubizhevsky
		Title: Chief Executive and Financial Officer

Two (2) separate mobile applications for providing medical marijuana patients in legal states within the United States, and through out Canada to locate nearby doctors, dispensaries and rate and review strains with a touch of your finger. The US based app also provides state-by-state current legislation, how to qualify for a medical marijuana 10 card and how a patient can take action by contacting their local advocacy group to get involved;

3·

All franchises, licenses, permits, consents, authorizations, approvals, and certificates of authority of any administrative or regulatory body found in Innovative’s name;

All proprietary rights, proprietary knowledge, know-how, designs, processes, trademarks and copyrights which Innovative owns or has a right to use in the operation of its business and all filings, registrations or issuances of any the foregoing with or by any federal, state, local or foreign regulatory, administrative or governmental office in connection therewith; and

All other contracts, and other agreements, contract rights, purchase orders, policies and understandings, whether oral or written, to which the Innovative is a party, and used in conducting the business and operations of the Innovative.

Per the terms of the Agreement, the Company did not assume any of the debts and/or liabilities of Innovative attached to the Assets. Based upon the quoted market price at the time of the execution of the Agreement, the aggregate purchase price is approximately $45,000.00. As a result of the Agreement, the Company owns informational software through mobile applications.

Although the purchased Assets do provide real data on medical marijuana, the applications in no way, in no capacity facilitate any sale or trafficking of medical or recreational marijuana.

The Agreement was executed as an arm’s length transaction and involved no related party.

Section 9

Financial Statements and Exhibits

ITEM 9.01

Financial Statements and Exhibits

10.1

Asset Purchase Agreement dated July 27, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BIOCUBE, INC.

Date: July 30, 2014

/s/ Boris Rubizhevsky

Boris Rubizhevsky

Chief Executive and Financial Officer

Filing Compare · BioCube, INC.